Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to two newly-hired employees as part of their employment inducement package. The grants, issued on February 28, 2025, total 13,525 shares of common stock with an exercise price of $1.85 per share, matching the closing price on the grant date.
The options are structured with a four-year vesting schedule, where 25% of shares vest after the first year, followed by quarterly vesting of the remaining 75%. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to Akebia's inducement award program terms and conditions.
Akebia Therapeutics (Nasdaq: AKBA) ha concesso opzioni su azioni a due nuovi dipendenti come parte del pacchetto di incentivazione all'assunzione. Le concessioni, emesse il 28 febbraio 2025, ammontano a 13.525 azioni ordinarie con un prezzo di esercizio di $1,85 per azione, corrispondente al prezzo di chiusura alla data della concessione.
Le opzioni sono strutturate con un programma di maturazione di quattro anni, in cui il 25% delle azioni matura dopo il primo anno, seguito da una maturazione trimestrale del restante 75%. Queste opzioni con scadenza di 10 anni sono state concesse ai sensi della Regola di quotazione Nasdaq 5635(c)(4) e sono soggette ai termini e alle condizioni del programma di incentivazione di Akebia.
Akebia Therapeutics (Nasdaq: AKBA) ha otorgado opciones sobre acciones a dos nuevos empleados como parte de su paquete de inducción laboral. Las concesiones, emitidas el 28 de febrero de 2025, totalizan 13,525 acciones ordinarias con un precio de ejercicio de $1.85 por acción, equivalente al precio de cierre en la fecha de concesión.
Las opciones están estructuradas con un programa de adquisición de cuatro años, donde el 25% de las acciones se adquiere después del primer año, seguido de una adquisición trimestral del 75% restante. Estas opciones, con un plazo de 10 años, se otorgaron bajo la Regla de Cotización Nasdaq 5635(c)(4) y están sujetas a los términos y condiciones del programa de inducción de Akebia.
Akebia Therapeutics (Nasdaq: AKBA)는 두 명의 신입 직원에게 고용 유인 패키지의 일환으로 주식 옵션을 부여했습니다. 2025년 2월 28일에 발행된 이 옵션은 총 13,525주로, 주당 $1.85의 행사 가격을 가지며, 이는 부여일의 종가와 일치합니다.
옵션은 4년의 베스팅 일정으로 구성되어 있으며, 첫 해에 25%의 주식이 베스트되고, 나머지 75%는 분기별로 베스팅됩니다. 이 10년 만기 옵션은 Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었으며, Akebia의 유인 보상 프로그램의 조건과 조항에 따릅니다.
Akebia Therapeutics (Nasdaq: AKBA) a accordé des options d'achat d'actions à deux nouveaux employés dans le cadre de leur package d'incitation à l'embauche. Les attributions, émises le 28 février 2025, totalisent 13 525 actions ordinaires avec un prix d'exercice de 1,85 $ par action, correspondant au prix de clôture à la date d'attribution.
Les options sont structurées avec un calendrier d'acquisition de quatre ans, où 25 % des actions acquièrent des droits après la première année, suivie d'une acquisition trimestrielle des 75 % restants. Ces options d'une durée de 10 ans ont été accordées conformément à la règle de cotation Nasdaq 5635(c)(4) et sont soumises aux termes et conditions du programme d'incitation d'Akebia.
Akebia Therapeutics (Nasdaq: AKBA) hat zwei neu eingestellten Mitarbeitern im Rahmen ihres Anreizpakets Aktienoptionen gewährt. Die Zuteilungen, die am 28. Februar 2025 ausgegeben wurden, umfassen insgesamt 13.525 Stammaktien mit einem Ausübungspreis von 1,85 $ pro Aktie, was dem Schlusskurs am Zuteilungsdatum entspricht.
Die Optionen sind mit einem vierjährigen Vesting-Plan strukturiert, bei dem 25 % der Aktien nach dem ersten Jahr fällig werden, gefolgt von einer vierteljährlichen Vesting der verbleibenden 75 %. Diese 10-jährigen Optionen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt und unterliegen den Bedingungen des Anreizprogramms von Akebia.
- None.
- None.
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 13,525 shares of Akebia’s common stock on February 28, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What are the terms of AKBA's new employee stock options granted on February 28, 2025?
How many shares were granted in AKBA's February 2025 employee inducement grants?
What is the vesting schedule for AKBA's February 2025 inducement stock options?
Under which Nasdaq rule were AKBA's February 2025 inducement grants issued?
